People · Operator
Named in public records as an officer, director or promoter · active 2008–2015 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| OrphoMed, Inc. | — | Biotechnology | Series B | $24.6M | $864.1M | 2015 |
| Attune Foods Inc | — | Other | Series A | $9.0M | $75.7M | 2008 |
Thomas D. Kiley at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Thomas D. Kiley on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Martin | 1 | 11 |
| Ilya B. Nykin | 1 | 5 |
| Frank Torti | 1 | 3 |
| Art Pappas | 1 | 3 |
| Roger E Wyse | 1 | 2 |
| Kenneth Widder | 1 | 2 |
| Joerg Reismeier | 1 | 1 |
| Nikhilesh Singh | 1 | 1 |
| Nikhilesh Singh, Ph.D. | 1 | 1 |
| Robert S Hurlbut | 1 | 1 |
| Jurgen B Auerbach | 1 | 1 |
| William B Rosenzweig | 1 | 1 |
| Richard B Boland | 1 | 1 |
| Roger B Wyse | 1 | 1 |
| Robert Hurlbut | 1 | 1 |
| Michael D. Chao | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.